{140 (selexipag 0.2 MG Oral Tablet [Uptravi]) / 60 (selexipag 0.8 MG Oral Tablet [Uptravi]... — RxCUI 1729076
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Selexipag: what it is, how it’s used, side effects, and interactions.
- Selexipag treats pulmonary arterial hypertension, a type of high blood pressure in the arteries of your lungs. It helps delay the disease getting worse and lowers the chance you'll...
- Tablets are taken by mouth twice a day and swallowed whole, so don't split or crush them. Taking them with food may help you tolerate them. Your doctor will raise your dose slowly,...
- Headache, diarrhea, nausea, jaw pain and muscle aches are common, especially while your dose is going up. Tell your doctor or pharmacist if they become hard to handle, since the do...
- Call right away if you have new or worsening shortness of breath, which could be fluid in the lungs. Also report symptoms that might suggest an overactive thyroid, or signs of an a...
🕸️ Concept Web — How {140 (selexipag 0.2 MG Oral Tablet [Uptravi]) /... Connects
RxCUI 1729076 Brand name pack · BPCK
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Selexipag
1729002IN
-
Selexipag
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Uptravi
1729008BN
-
Uptravi
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Selexipag Oral Tablet
1729006SCDF -
Selexipag Oral Product
1729004SCDG -
Selexipag Pill
1729005SCDG -
Selexipag Oral Tablet [Uptravi]
1729010SBDF -
Uptravi Oral Product
1729011SBDG -
Uptravi Pill
1729012SBDG -
Pack
746839DF -
Oral Product
1151131DFG - +1 more in this family
-
Selexipag Oral Tablet
-
Clinical & branded drugs 8
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Selexipag 0.2 MG Oral Tablet
1729051SCD -
Selexipag 0.8 MG Oral Tablet
1729063SCD -
Selexipag 0.2 MG
1729050SCDC -
Selexipag 0.8 MG
1729062SCDC -
Selexipag 0.2 MG Oral Tablet [Uptravi]
1729053SBD -
Selexipag 0.8 MG Oral Tablet [Uptravi]
1729065SBD -
Selexipag 0.2 MG [Uptravi]
1729052SBDC -
Selexipag 0.8 MG [Uptravi]
1729064SBDC
-
Selexipag 0.2 MG Oral Tablet
-
Packs 1
Fixed collections of drugs packaged and sold together, like dose packs.
🔀 Generic ⇄ Brand Crosswalk
Generic (Clinical) Concepts
-
Selexipag 0.2 MG Oral Tablet
SCD · 1729051 -
Selexipag 0.8 MG Oral Tablet
SCD · 1729063 -
{140 (selexipag 0.2 MG Oral Tablet) / 60 (selexipag 0.8 MG Oral Tablet) } Pack
GPCK · 1729075 -
Selexipag 0.2 MG
SCDC · 1729050 -
Selexipag 0.8 MG
SCDC · 1729062 -
Selexipag Oral Tablet
SCDF · 1729006 -
Selexipag Oral Product
SCDG · 1729004 -
Selexipag Pill
SCDG · 1729005
Brand-Name Concepts
-
Selexipag 0.2 MG Oral Tablet [Uptravi]
SBD · 1729053 -
Selexipag 0.8 MG Oral Tablet [Uptravi]
SBD · 1729065 -
Selexipag 0.2 MG [Uptravi]
SBDC · 1729052 -
Selexipag 0.8 MG [Uptravi]
SBDC · 1729064 -
Selexipag Oral Tablet [Uptravi]
SBDF · 1729010 -
Uptravi Oral Product
SBDG · 1729011 -
Uptravi Pill
SBDG · 1729012 -
Uptravi
BN · 1729008
📦 FDA Products & Package NDCs
12 products · 13 package NDCs
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 66215-0602-06 | 1 BOTTLE in 1 CARTON (66215-602-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0602-14 | 1 BOTTLE in 1 CARTON (66215-602-14) / 140 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0604-06 | 1 BOTTLE in 1 CARTON (66215-604-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0606-06 | 1 BOTTLE in 1 CARTON (66215-606-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0608-06 | 1 BOTTLE in 1 CARTON (66215-608-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0610-06 | 1 BOTTLE in 1 CARTON (66215-610-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0612-06 | 1 BOTTLE in 1 CARTON (66215-612-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0614-06 | 1 BOTTLE in 1 CARTON (66215-614-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0616-06 | 1 BOTTLE in 1 CARTON (66215-616-06) / 60 TABLET, COATED in... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0628-20 | 1 KIT in 1 CARTON (66215-628-20) * 1 BOTTLE in 1 CARTON /... | UPTRAVI Titration Pack | Actelion Pharmaceuticals US, Inc. | 2015-12-21 |
| 66215-0718-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (66215-718-01) / 10 mL in 1... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2021-07-29 |
| 66215-0910-14 | 1 BOTTLE in 1 CARTON (66215-910-14) / 140 TABLET, FILM COAT... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2026-05-23 |
| 66215-0915-14 | 1 BOTTLE in 1 CARTON (66215-915-14) / 140 TABLET, FILM COAT... | UPTRAVI | Actelion Pharmaceuticals US, Inc. | 2026-05-23 |
🗃️ Sources & Limits
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.